Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. Georges Pompidou European Hospital, Paris, France

Survival: 18.4 months
Toxicity Grade: 4
Treatments: Chemotherapy
Drugs: Emcyt
Country: France
City/State/Province: Paris
Hospital: Georges Pompidou European Hospital
Journal: Link
Date: 5/2005

Patients: This Phase II study enrolled 130 men, who were randomized into three groups. Group B had 42 men (median age 68) with hormonal-resistant prostate cancer. In 39 patients, metastatic sites involved up to two organs; the remaining three patients had metastatic sites in three or more organs. Metastatic sites included bone and lymph node tissue.

Treatment: The treatment for group B involved three chemotherapeutic agents: docetaxel (intravenous), estramustine (oral), and prednisone.

Toxicities: Grade 3-4 toxicities in group B included thrombocytopenia and thrombosis.

Results: For group B, the overall median survival was 18.4 months.

Support: Authors of this study had been employees, consultants, or honorarium recipients for Aventis. Aventis manufactures docetaxel.

Correspondence: Stephane Oudard, MD.

E-mail to a Friend Email Physician More Information